Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage

Lignende værker

• Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma
  af: Stein, Wilfred D., et al.
  Udgivet: (2009)
• Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
  af: Burotto, Mauricio, et al.
  Udgivet: (2014)
• Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate constant as an indicator of therapeutic efficacy
  af: Stein, Wilfred D., et al.
  Udgivet: (2010)
• Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data
  af: Stein, Wilfred D., et al.
  Udgivet: (2008)
• Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
  af: Krastan B. Blagoev, et al.
  Udgivet: (2013-02-01)